Nothing about sarcoidosis is easy. First identified in 1877, it is quite common. In the United States, lifetime risk is 2.4% and 0.85% for African American persons and White persons, respectively.

Please provide your email address to receive an email when new articles are posted on . Patients treated with the JAK inhibitor tofacitinib saw a dose-dependent response in the treatment of cutaneous ...

Task force members from the European Respiratory Society evaluated available evidence for treatment of various manifestations of sarcoidosis but said their recommendations were not the last word. As ...

Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure. While some patients with sarcoidosis have spontaneous ...

CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at ...

Please provide your email address to receive an email when new articles are posted on . In a retrospective cohort study, Marc A. Judson, MD, professor of medicine and chief of pulmonary and critical ...

– Retrospective analysis suggests Acthar Gel treatment was associated with similar improvement in health status and overall symptom reduction in African Americans and non-African Americans with ...

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...